TaiMed Biologics(4147) Confirms Continuity of Trogarzo® Partnership Amidst Future Pak Acquisition of Theratechnologies

TaiMed Biologics, Inc. (4147) acknowledges the recent announcement that Theratechnologies, the exclusive commercialization partner for Trogarzo® (ibalizumab-uiyk) in the United States of America, has entered into a definitive agreement to be acquired by CB Biotechnology (an affiliate of Future Pak) for US$3.01 per share in cash plus one contingent value right (CVR) per share—valued at up to US$1.19 each—totaling up to US$254 million. The deal is expected to close in the fourth quarter of 2025, pending shareholder and court approvals. Theratechnologies Inc. Key points: 一、Partnership certainty: TaiMed's longstanding agreement with Theratechnologies for marketing and distributing Trogarzo in the U.S. and Canada remains in effect and unaffected by Future Pak's acquisition. 二、Operational continuity: Trogarzo remains a critical therapy for people living with multidrug-resistant HIV 1. TaiMed expects uninterrupted efforts in commercialization, ongoing clinical support, and regulatory liaison. 三、Future Pak backing: The acquisition underscores confidence in Theratechnologies's product platforms—Trogarzo and EGRIFTA®—with milestone-linked CVRs contingent upon combined franchise

The release as fetched from its publisher. taimedbiologics.com ↗